2026-2034年小分子药物研发原料药及CDMO全球市场规模、份额、趋势及成长分析报告

小分子药物发现原料药CDMO市场预计将从2025年的528.7亿美元成长到2034年的813.9亿美元，2026年至2034年的复合年增长率为4.91%。

受製药生产外包趋势日益增长的推动，全球小分子药物研发原料药（API）合约开发与生产组织（CDMO）市场正经历强劲成长。药物研发公司正与合约开发与生产组织（CDMO）合作，以降低成本并缩短药物研发週期。对复杂小分子药物和特殊原料药的需求不断增长，推动了市场扩张，而日益严格的监管要求也促使企业更加依赖经验丰富的CDMO合作伙伴。

主要驱动因素包括新药核准数量的增加和药物研发管线的扩展。合约研发生产机构（CDMO）在製程优化、规模化生产和法规遵从方面提供专业知识。研发投入的成长和对效率提升的重视正在推动外包活动。此外，对灵活生产能力和先进技术的需求也支撑着该产业的持续成长。

展望未来，随着製药公司优先发展策略联盟，市场预计将进一步成长。连续生产和绿色化学领域的技术进步将提高生产效率。新兴市场凭藉其成本优势和熟练劳动力资源，正成为极具吸引力的外包目的地。随着小分子疗法的不断创新，合约研发生产机构（CDMO）的角色将日益重要。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球小分子药物研发原料药/合约研发生产机构市场：依阶段类型划分

• 市场分析、洞察与预测
• 临床前阶段
• 临床阶段
• 商业阶段

第五章：全球小分子药物发现原料药CDMO市场：依客户类型划分

• 市场分析、洞察与预测
• 製药
• 生物技术

第六章：全球小分子药物研发原料药/合约研发生产机构市场：依治疗领域划分

• 市场分析、洞察与预测
• 心血管疾病
• 肿瘤学
• 神经病学
• 代谢性疾病
• 感染疾病
• 呼吸系统疾病
• 其他的

第七章 全球小分子药物发现原料药CDMO市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Lonza Group Ltd
  • Novo Holdings（Catalent Inc.）
  • Thermo Fisher Scientific Inc
  • Siegfried Holding AG
  • Recipharm AB
  • Cordenpharma International
  • Jubilant Life Sciences（Jubilant Biosys Ltd.）
  • Wuxi AppTec Co. Ltd
  • Merck KGaA
  • Ajinomoto Bio-Pharma Services Inc

The Small Molecule Innovator API CDMO Market size is expected to reach USD 81.39 Billion in 2034 from USD 52.87 Billion (2025) growing at a CAGR of 4.91% during 2026-2034.

The Global Small Molecule Innovator API CDMO Market is experiencing strong growth due to increasing outsourcing trends in pharmaceutical manufacturing. Innovator companies are partnering with Contract Development and Manufacturing Organizations (CDMOs) to reduce costs and accelerate drug development timelines. Rising demand for complex small molecule drugs and specialty APIs is driving market expansion. Growing regulatory requirements also encourage companies to rely on experienced CDMO partners.

Key drivers include the rising number of new drug approvals and expanding pharmaceutical pipelines. CDMOs provide expertise in process optimization, scale-up production, and regulatory compliance. Increasing R&D expenditure and focus on efficiency improvements enhance outsourcing activities. Additionally, the need for flexible manufacturing capabilities and access to advanced technologies supports sustained growth in the sector.

Looking ahead, the market is expected to grow further as pharmaceutical companies prioritize strategic collaborations. Technological advancements in continuous manufacturing and green chemistry will improve production efficiency. Emerging markets are becoming attractive outsourcing hubs due to cost advantages and skilled labor availability. As innovation in small molecule therapeutics continues, the role of CDMOs will remain increasingly critical.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Stage Type

• Preclinical
• Clinical
• Commercial

By Customer Type

• Pharmaceutical
• Biotechnology

By Therapeutic Area

• Cardiovascular Diseases
• Oncology
• Neurology
• Metabolic Disorders
• Infectious Diseases
• Respiratory Disorders
• Others

COMPANIES PROFILED

• Lonza Group Ltd, Novo Holdings Catalent Inc, Thermo Fisher Scientific Inc, Siegfried Holding AG, Recipharm AB, Cordenpharma International, Jubilant Life Sciences Jubilant Biosys Ltd, Wuxi AppTec Co Ltd, Merck KGaA, Ajinomoto BioPharma Services Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY STAGE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Stage Type
• 4.2. Preclinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY CUSTOMER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Customer Type
• 5.2. Pharmaceutical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Biotechnology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Therapeutic Area
• 6.2. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Respiratory Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Stage Type
  • 7.2.2 By Customer Type
  • 7.2.3 By Therapeutic Area
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Stage Type
  • 7.3.2 By Customer Type
  • 7.3.3 By Therapeutic Area
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Stage Type
  • 7.4.2 By Customer Type
  • 7.4.3 By Therapeutic Area
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Stage Type
  • 7.5.2 By Customer Type
  • 7.5.3 By Therapeutic Area
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Stage Type
  • 7.6.2 By Customer Type
  • 7.6.3 By Therapeutic Area
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SMALL MOLECULE INNOVATOR API CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Lonza Group Ltd
  • 9.2.2 Novo Holdings (Catalent Inc.)
  • 9.2.3 Thermo Fisher Scientific Inc
  • 9.2.4 Siegfried Holding AG
  • 9.2.5 Recipharm AB
  • 9.2.6 Cordenpharma International
  • 9.2.7 Jubilant Life Sciences (Jubilant Biosys Ltd.)
  • 9.2.8 Wuxi AppTec Co. Ltd
  • 9.2.9 Merck KGaA
  • 9.2.10 Ajinomoto Bio-Pharma Services Inc